Hear Dr. Emily Lupton on her lab's investigation whether photoacoustic imaging (PAI) could provide novel imaging in the heart after angiotensin-II induced hypertrophy with and without treatment with losartan.
An estimated 1.28 billion adults worldwide are living with hypertension which can initiate cardiac hypertrophy and increase the risk of cardiovascular diseases. New imaging diagnostics could identify those most at risk, allowing early stratification of treatments. Photoacoustic imaging (PAI) can quantify blood oxygen saturation in deep tissue and could offer important data on cardiac remodeling in hypertension. Angiotensin-II mice showed key characteristics of hypertrophy, including increased wall thickness and LV mass. After angiotensin-II infusion, mice showed significantly reduced blood oxygen saturation than baseline. Angiotensin-II mice treated with losartan did not differ from controls. The findings indicate that PAI is sensitive to the insufficiency in O2 supply that exists in cardiac hypertrophy. Importantly, losartan prevented these changes, indicating that PAI does not only offer an important biomarker of disease, but can also evaluate the efficacy of clinically relevant therapies.
Key Topics Include:
- Photoacoustic imaging can measure reduced oxygen supply in the enlarged hypertrophic heart with insufficient angiogenesis
- The angiotensin II receptor blocker, Losartan, prevented changes in oxygenation which could be imaged with PAI, demonstrating how PAI can be used to monitor therapies
Presenters
Research Associate
King’s College London
Webinar Host
FUJIFILM VisualSonics Inc.
